Tag: Revolving Door
For STAT, Ed Silverman reports on growing concerns about the industry ties of the new nominee for FDA commissioner. “The nomination comes at a...
The BMJ reports that renewed concerns about the “revolving door” between government and industry have been sparked by the health minister of England’s decision to join to drug company Roche.
Bernie Sanders joins numerous public health groups and opposes Robert Califf's nomination to lead the FDA over industry ties.
Sheila Kaplan for the Boston Globe reports that Dr. Robert Califf, the Obama administration's nominee to lead the Food and Drug Administration (FDA), has removed his name from a series of scientific papers that he recently coauthored. The decision to remove his name, against publication ethics standards, has brought Califf under renewed criticism.
On Tuesday, the Obama administration nominated Dr. Robert Califf to be the new commissioner of the Food and Drug Administration (FDA). In a statement, director of the Public Citizen’s Health Research Group, Dr. Michael Carome called on the Senate to reject the nomination. He contends that Califf “racked up a long history of extensive financial ties to multiple drug and medical device companies, including Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme and Sanofi-Aventis, to name a few.”